U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07006792) titled 'A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden' on May 28.
Brief Summary: The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy.
Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis
Intervention:
DRUG: Lebrikizumab
Administered SC
Recruitmen...